Drugs / XmAb657
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07284797 | Feb 2026 → Oct 2028 expected | Sjogren syndrome, idiopathic inflammatory myopathy, systemic sclerosis | Xencor, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XmAb657 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07284797 ↗ |
| Route | Subcutaneous | “given XmAb657 subcutaneously (SC) by injection under the skin” NCT07284797 ↗ |